Thursday, April 19, 2012

Hepatitis c drug

  • Boehringer Ingelheim GmbH said its experimental hepatitis C oral treatment cleared the virus in as many as 82 percent of patients in a study.
  • (Bloomberg)
  • A regimen combining experimental drugs from Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) suppressed the hepatitis C virus in most patients four weeks after completing treatment, according to a new study.
  • (NASDAQ)
  • A drug interaction study of TMC435 with Bristol-Myers an analyst at Danske Bank, in a note to investors.
  • (Bloomberg)
  • Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) said Phase I clinical trial results showed a single dose of the hepatitis C virus treatment IDX719 achieved potent viral load reductions.
  • (Marketwatch)
  • A commitment to people with hepatitis C Headquartered in Belgium, Janssen Therapeutics EMEA is committed to the further development and commercialization of its investigational drug TMC435 in the EMEA region.
  • (Yahoo Finance)
  • A regimen combining experimental drugs from Gilead Sciences Inc. (NASDAQ:GILD) and Bristol-Myers Squibb Co. (NYSE:BMY) suppressed the hepatitis C virus in most patients four weeks after completing treatment, according to a new study.
  • (Marketwatch)
  • Further investigation of GS-7977 in a variety of patient populations and combinations will be important in assessing the drugs potential as part of an all-oral regimen for hepatitis C.
  • (TMCnet)
  • Achillion Pharmaceuticals (ACHN) has no FDA approved drugs on the market. Achillion is currently focusing on developing its hepatitis C drug ACH-1625, which is ending Phase 2 clinical trials.
  • (Seekingalpha.com)
  • As a result, the replication of the virus is effectively inhibited and the level of Hepatitis C virus is profoundly reduced.
  • (PR Newswire)

No comments:

Post a Comment